CN102171208A - 用作体内显像剂的靛红衍生物 - Google Patents

用作体内显像剂的靛红衍生物 Download PDF

Info

Publication number
CN102171208A
CN102171208A CN2009801389781A CN200980138978A CN102171208A CN 102171208 A CN102171208 A CN 102171208A CN 2009801389781 A CN2009801389781 A CN 2009801389781A CN 200980138978 A CN200980138978 A CN 200980138978A CN 102171208 A CN102171208 A CN 102171208A
Authority
CN
China
Prior art keywords
compound
caspase
isatin
substituted
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801389781A
Other languages
English (en)
Chinese (zh)
Inventor
E·O·阿博格
G·史密斯
Q-D·阮
E·阿斯塔德
M·E·格拉泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
GE Healthcare AS
Original Assignee
Imperial Innovations Ltd
Amersham Health AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0816294A external-priority patent/GB0816294D0/en
Priority claimed from GB0818076A external-priority patent/GB0818076D0/en
Application filed by Imperial Innovations Ltd, Amersham Health AS filed Critical Imperial Innovations Ltd
Publication of CN102171208A publication Critical patent/CN102171208A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2009801389781A 2008-09-05 2009-09-04 用作体内显像剂的靛红衍生物 Pending CN102171208A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0816294.3 2008-09-05
GB0816294A GB0816294D0 (en) 2008-09-05 2008-09-05 Compounds
GB0818076.2 2008-10-02
GB0818076A GB0818076D0 (en) 2008-10-02 2008-10-02 Compounds
PCT/GB2009/002132 WO2010026388A1 (en) 2008-09-05 2009-09-04 Isatin derivatives for use as in vivo imaging agents

Publications (1)

Publication Number Publication Date
CN102171208A true CN102171208A (zh) 2011-08-31

Family

ID=41181051

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801389781A Pending CN102171208A (zh) 2008-09-05 2009-09-04 用作体内显像剂的靛红衍生物

Country Status (10)

Country Link
US (1) US8961930B2 (enExample)
EP (1) EP2367816B1 (enExample)
JP (1) JP5667056B2 (enExample)
KR (1) KR20110066927A (enExample)
CN (1) CN102171208A (enExample)
AU (1) AU2009289062B2 (enExample)
CA (1) CA2735970A1 (enExample)
MX (1) MX2011002498A (enExample)
RU (1) RU2535975C2 (enExample)
WO (1) WO2010026388A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103183631A (zh) * 2011-12-28 2013-07-03 天津市国际生物医药联合研究院 新颖的靛红-5-磺酰胺类衍生物及其在制备治疗非典型性肺炎的药物中的应用
CN115171929A (zh) * 2021-04-01 2022-10-11 中核核电运行管理有限公司 重水堆机组给水支管与燃料通道小间隙问题处理的方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2828810A1 (en) 2011-03-01 2012-09-07 Ge Healthcare Limited Radiolabelled octreotate analogues as pet tracers
GB201121911D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Radiofluorination method
EP3456718B1 (en) * 2016-05-10 2021-02-17 Fundaçâo Oswaldo Cruz Isatin-derived compounds, use of the compounds for the treatment of aids and hbv infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1240648A (en) 1967-08-16 1971-07-28 Wyeth John & Brother Ltd N-substituted isatins
AR016384A1 (es) 1997-07-30 2001-07-04 Smithkline Beecham Corp Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta.
AU7625500A (en) 1999-09-30 2001-04-30 Smithkline Beecham Corporation Caspases and apoptosis
PT1255752E (pt) * 2000-02-15 2007-10-17 Pharmacia & Upjohn Co Llc Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo
RU2259999C2 (ru) * 2003-08-26 2005-09-10 ООО "Исследовательский институт химического разнообразия" 1-сульфонил-1,3-дигидроиндол-2-оны, фармацевтические композиции (варианты), способ их получения и применения
GB0327494D0 (en) 2003-11-26 2003-12-31 Amersham Plc Novel imaging agents
US7270799B2 (en) 2004-01-15 2007-09-18 Nst Neurosurvival Technologies Ltd. Perturbed membrane-binding compounds and methods of using the same
US7256198B2 (en) * 2004-02-18 2007-08-14 Wyeth Pyrimidoindolones and methods for using same
GB0428012D0 (en) 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
AU2005324905B2 (en) * 2005-01-17 2012-01-19 Universitaetsklinikum Muenster 5-pyrrolidinylsulfonyl isatin derivatives

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103183631A (zh) * 2011-12-28 2013-07-03 天津市国际生物医药联合研究院 新颖的靛红-5-磺酰胺类衍生物及其在制备治疗非典型性肺炎的药物中的应用
CN103183631B (zh) * 2011-12-28 2016-08-24 天津市国际生物医药联合研究院 靛红-5-磺酰胺类衍生物及其在制备治疗非典型性肺炎的药物中的应用
CN115171929A (zh) * 2021-04-01 2022-10-11 中核核电运行管理有限公司 重水堆机组给水支管与燃料通道小间隙问题处理的方法

Also Published As

Publication number Publication date
AU2009289062A1 (en) 2010-03-11
US20110195024A1 (en) 2011-08-11
EP2367816B1 (en) 2016-11-09
AU2009289062B2 (en) 2015-01-22
JP5667056B2 (ja) 2015-02-12
RU2011112075A (ru) 2012-10-10
CA2735970A1 (en) 2010-03-11
RU2535975C2 (ru) 2014-12-20
JP2012502014A (ja) 2012-01-26
MX2011002498A (es) 2011-08-04
KR20110066927A (ko) 2011-06-17
EP2367816A1 (en) 2011-09-28
WO2010026388A1 (en) 2010-03-11
US8961930B2 (en) 2015-02-24

Similar Documents

Publication Publication Date Title
TWI699363B (zh) 四氫-吡啶并［３，４-ｂ］吲哚雌激素受體調節劑及其用途
CN111936501B (zh) 布鲁顿酪氨酸激酶降解剂
EP2986609B1 (en) Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
EP3508487B1 (en) Pyrazolo[1,5-a]pyrimidine compound
PH12014501230B1 (en) Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
EP3986902B1 (en) Macrocyclic inhibitors of mcl-1
CN106536491B (zh) 作为盐皮质激素受体调节剂的苯并噁嗪酮酰胺
EA017713B1 (ru) [f-18]-меченая l-глутаминовая кислота, [f-18]-меченый l-глутамин, их производные и их применение, а также способ их получения
CN118355019A (zh) 苯并嘧啶类化合物及其应用
KR101879431B1 (ko) 황화수소 검출용 방사성 프로브
CN102171208A (zh) 用作体内显像剂的靛红衍生物
JP2021516229A (ja) 低親和性ポリ（ａｄ−リボース）ポリメラーゼ１依存性細胞毒性剤
EP3281643A2 (en) Radioactive probe for detecting hydrogen sulfide
US20240391896A1 (en) Small molecule compound targeting bcl9/beta-catenin interaction
CN106905303A (zh) 一类靶向fak的化合物和其标记物、及它们的制备方法和应用
CN113135895A (zh) 一种新型联苯类衍生物及其制备方法与医药用途
US20230029194A1 (en) Macrocylic sulfonyl derivatives mcl-1 inhibitors
US20090068105A1 (en) Isatin analogues and uses therefor
AU2023285721B2 (en) Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
RU2822386C2 (ru) Макроциклические ингибиторы mcl-1
RU2811207C1 (ru) Fgfr и его ингибитор мутаций, способ его получения и его применение
HK40108118A (en) Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
WO2021123291A1 (en) Oga inhibitor compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110831